Safety, Tolerability and Pharmacokinetics of Open Label Sarcosine Added on to Anti-Psychotic Treatment in Schizophrenia -- Preliminary Study.

MLA

Amiaz, Revital, et al. “Safety, Tolerability and Pharmacokinetics of Open Label Sarcosine Added on to Anti-Psychotic Treatment in Schizophrenia -- Preliminary Study.” Israel Journal of Psychiatry & Related Sciences, vol. 52, no. 1, Mar. 2015, pp. 12–16. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=102931635&authtype=sso&custid=ns315887.

APA

Amiaz, R., Kent, I., Rubinstein, K., Sela, B. A., Javit, D., & Weiser, M. (2015). Safety, Tolerability and Pharmacokinetics of Open Label Sarcosine Added on to Anti-Psychotic Treatment in Schizophrenia -- Preliminary Study. Israel Journal of Psychiatry & Related Sciences, 52(1), 12–16.

Chicago

Amiaz, Revital, Ilan Kent, Katya Rubinstein, Ben Ami Sela, Daniel Javit, and Mark Weiser. 2015. “Safety, Tolerability and Pharmacokinetics of Open Label Sarcosine Added on to Anti-Psychotic Treatment in Schizophrenia -- Preliminary Study.” Israel Journal of Psychiatry & Related Sciences 52 (1): 12–16. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=102931635&authtype=sso&custid=ns315887.